Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells, according to a new study published in Nanoscale. The study, conducted in partnership by researchers at Nemours Children’s Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.
“High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor. This research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient’s health,” said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children’s Health System and senior author of the study. “Unique approaches to target tumor cells with nanoparticle delivery systems hold promise for treatment of resistant tumors, such as the high risk neuroblastoma. We are hopeful that in the future, nanoparticles can be utilized to personalize care to patients and reduce the late effects of therapy.”
Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys. About 700 new cases of neuroblastoma are diagnosed each year in the United States and most cases appear in children younger than 5 years old. High-risk neuroblastoma is hard to cure and is more likely to become resistant to standard therapies or recur. These cancers are also associated with late effects after treatments have ended, including developmental delays, hearing loss, or other disabilities.
Curcumin has been shown to have substantial anti-cancer ability, but its low solubility and poor stability have made its use in medicinal applications challenging. Researchers from Nemours and UCF found that nanoparticles can be used to deliver curcumin to tumor sites.
“This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,” said Professor Sudipta Seal, who directs of UCF’s NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study. “More research is needed, but we are hopeful it could lead to more effective treatment of this devastating disease in the future.”
In the study, researchers loaded Cerium oxide nanoparticles with curcumin and coated them with dextran to test in cell lines of a high-risk form of neuroblastoma, known as MYCN-amplified, as well as non-amplified neuroblastoma. This formulation induced substantial cell death in neuroblastoma cells while producing no or only minor toxicity in healthy cells. Overall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.
Nanoscience research, which explores the unusual properties of materials at the nanoscale, has led to advancements in medicine, energy, information storage, computing and other fields. At no more than 100 nanometers, nanoparticles are exceedingly small. By comparison, a sheet of paper is about 75,000 nanometers thick.
This study was conducted in a laboratory setting in Orlando, at Nemours Children’s Hospital and the University of Central Florida in cells from children with neuroblastoma, but researchers hope to begin to use these curcumin nanoparticles with micro RNA in animal models to direct the molecule to a tumor site.
The Latest on: Neuroblastoma
- Mother 'desperately' fundraising for new pioneering treatment to save sons lifeon March 22, 2020 at 1:16 am
The day after welcoming Kylie, Liam's diagnosis was confirmed as neuroblastoma, and Claire and Mike were told he would have to endure intense chemotherapy, before undergoing surgery to remove his ...
- Ten Challenges in the Management of Neuroblastomaon March 19, 2020 at 5:00 pm
The current multimodality therapy of high-risk neuroblastoma therefore includes a 'maintenance' phase of treatment at the end of therapy aimed at the eradication of MRD. The question as to whether ...
- Molecular Characterization and Classification of Neuroblastomaon March 18, 2020 at 5:00 pm
The possibility of efficiently generating a wealth of genome-wide genetic and gene-expression data has undoubtedly led to a substantial improvement of our understanding of neuroblastoma ...
- Neuroblastoma Australia’s 2020 Run2Cure to fund vital researchon March 17, 2020 at 9:31 pm
Neuroblastoma is currently the leading cause of cancer deaths in children under the age of five. This is a statistic that Neuroblastoma Australia is determined to change. The national charity’s ...
- PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020on March 17, 2020 at 5:00 am
PV-10 is also undergoing preclinical study for pediatric solid tumor cancers (like neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma) and pediatric blood cancers (like leukemia). 5,6 ...
- 'He'll always be my superhero': The Bradley Lowery Foundation unveils holiday home nameon March 13, 2020 at 9:00 am
Bradley, from Blackhall Colliery, County Durham, lost his battle with neuroblastoma aged six in July 2017, but those around him want to ensure his legacy lives on. Football-mad Bradley stole the ...
- Kuur Therapeutics Launches to Develop and Commercialize “Off-the-shelf” CAR-NKT Cell Therapies Targeting Hematological and Solid Tumorson March 10, 2020 at 9:29 am
IP Group, Baylor College of Medicine and Schroeder Adveq are investing to support two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neuroblastoma) and ANCHOR (allogeneic CAR-NKT cells in ...
- Dubbo's Mitchell Ray has been diagnosed with the rare neuroblastomaon March 9, 2020 at 11:00 am
Dad Jeremy, a security officer at Dubbo City Regional Airport, hasn't left Mitchell's side since he was diagnosed with the rare neuroblastoma in mid-January and flown to the Sydney hospital's ...
- Cannonball kids: Finding options for kids with canceron March 6, 2020 at 4:13 am
Leukemia, neuroblastoma, bone cancer and Wilms tumor are just a few of the cancers that can affect children. Some cancers have very effective therapies but many do not, leaving families with few or no ...
- Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibitionon March 2, 2020 at 8:09 am
Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24:65–86.
via Google News and Bing News